This cluster reflects routine option exercises and modest share sales for tax and personal liquidity purposes, not a signal of fundamental concern. Monitor for any acceleration in open-market selling, but current activity is within normal range for executives managing equity compensation.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $530.35entry
- T+1 · 8mo ago −0.63%α −0.39% · $527.00
- T+5 · 8mo ago +2.12%α +2.82% · $541.60
- T+20 · 7mo ago +9.46%α +3.38% · $580.51
- T+60 · 5mo ago +2.94%α −9.20% · $545.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon exercised stock options and sold shares in the open market, generating over $3.7 million in proceeds. The activity is part of a routine stock option exercise and partial sale of shares, not an outright open-market sell-off of owned shares. Director Judy Olian also sold a small portion of her holdings.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt exercised options for 38,000 shares (across multiple tranches) at $146.03 and $0 strike prices, with total intrinsic value of $4.17 million.
- Rothblatt sold 679 shares in open-market transactions totaling $356,253 in proceeds.
- EVP Paul Mahon exercised options for 16,600 shares at $146.03, with intrinsic value of $2.42 million, and sold 753 shares for $397,184.
- Director Judy Olian sold 200 shares for $106,000 in an open-market transaction.
- Total open-market sales by insiders: $859,437 over 7 days, consistent with recent 30-day trend of $839K in sales.
- Non-cash transactions (option exercises at $0) are administrative and do not reflect economic activity.
Financial Impact
$859,437 in open-market sales over 7 days; total derivative exercises valued at $6.59 million (non-cash). Total insider selling represents 0.0038% of $22.8B market cap.
Risk Factors
- Perception risk if media or investors misinterpret option exercises and related sales as negative sentiment.
- Minor dilution from exercised options, though negligible relative to company size.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (13 trades, 7d window) | cluster-UTHR-1774384344570 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers